B-Lymphoblastic Leukemia / Lymphoma · line 1 · POMP maintenance — B-ALL post-induction-consolidation (vincristine + 6-MP + MTX + prednisone)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-POMP-B-ALL-MAINTENANCE |
| ID | IND-B-ALL-POST-CONSOLIDATION-POMP-MAINTENANCE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-B-ALL |
| Sources | SRC-CALGB-10403-STOCK-2019 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead signoff. Standard-track maintenance for B-ALL post-induction-consolidation. line_of_therapy: 1 reflects 1L pathway continuation (analogous to MM lenalidomide and AML QUAZAR patterns). Engine should activate after consolidation + interim maintenance + delayed intensification phases complete with confirmed CR. For Ph+ B-ALL, runs alongside continued TKI per institutional protocol.
Used By
No reverse references found in the YAML corpus.